Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 12, 2020

SELL
$1.71 - $5.87 $171,607 - $589,083
-100,355 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$2.78 - $4.7 $278,986 - $471,668
100,355 New
100,355 $377,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Pinz Capital Management, LP Portfolio

Follow Pinz Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinz Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pinz Capital Management, LP with notifications on news.